With more and more drug-resistant Staphylococcus aureus strains emerging in hospitals, there is an urgent need to develop an effective vaccine to combat S. aureus infection. In this study, we constructed a novel bivalent fusion vaccine, SpA-D_KKAA-FnBPA_37-507 (SF), based on the D domain of staphylococcal protein A (SpA) and the A domain of fibronectin-binding protein A (FnBPA). Immunisation with SF induced a more ideal protective effect compared with the single components alone in a sepsis model. It also showed broad immunoprotection against seven FnBPA isotypes. Vaccination with SF induced strong antibodies responses and Th1/Th17 polarized cellular responses. Further we demonstrated the protective effect of antibodies by the opsonophagocytic assay (OPA) and passive immunisation. Moreover, vaccination with SF showed protective efficacy in a murine pneumonia model and skin abscess model. These results suggest that SF can be regarded as a promising vaccine candidate for the prevention of S. aureus infections.

随着医院中出现越来越多的耐药金黄色葡萄球菌菌株，迫切需要开发一种有效的疫苗来对抗金黄色葡萄球菌感染。在这项研究中，我们构建了一种新型的二价融合疫苗SpA-D _KKAA -FnBPA _37-507（SF），基于葡萄球菌蛋白A（SpA）的D结构域和纤连蛋白结合蛋白A（FnBPA）的A结构域。与脓毒症模型中的单个成分相比，SF免疫诱导出更理想的保护作用。它还显示出对7种FnBPA同种型的广泛免疫保护。用SF疫苗接种可诱导强烈的抗体反应和Th1 / Th17极化的细胞反应。此外，我们通过调理吞噬试验（OPA）和被动免疫证明了抗体的保护作用。而且，SF疫苗接种在鼠肺炎模型和皮肤脓肿模型中显示出保护作用。这些结果表明，SF可以被认为是预防金黄色葡萄球菌感染的有希望的疫苗候选者。